Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) for Advanced Melanoma in Anti-Programmed Death-1/Programmed Death-Ligand 1 (PD-1/L1)-Exposed Participants (MK-7902-004/E7080-G000-225/LEAP-004)

Completed · Phase 2

Conditions studied: Advanced Melanoma

In brief

This study will evaluate the safety and efficacy of combination therapy of lenvatinib (E7080/MK-7902) and pembrolizumab following approximately 2 years of pembrolizumab therapy and approximately 2 years or more lenvatinib therapy in adult participants with unresectable or advanced melanoma who have been exposed to anti-programmed cell death ligand 1 (PD-1/L1) agents approved for unresectable or metastatic melanoma. No statistical hypothesis will be tested in this study.

Key facts

Study ID: NCT03776136
Run by: Merck Sharp & Dohme LLC
People needed: 103
Starts: 2019-01-30
Expected to finish: 2023-10-11
Last updated by the study team: 2024-10-09

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Has histologically or cytologically confirmed melanoma
Has unresectable Stage III or Stage IV melanoma per American Joint Committee on Cancer (AJCC) staging system version 8 that is not amenable to local therapy
Has the presence of ≥1 measurable lesion by computed tomography (CT) or magnetic resonance imaging (MRI) per RECIST 1.1 as confirmed by BICR.
Has progressed on treatment with an anti-PD-1/L1 monoclonal antibody (mAb) administered either as monotherapy, or in combination with other checkpoint inhibitors or other therapies
Has submitted pre-trial imaging
Has an Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1
Has provided a baseline tumor biopsy
Has resolution of toxic effect(s) of the most recent prior therapy to Grade 1 or less (except alopecia). If participant received major surgery or radiation therapy of >30 Gray (Gy), they must have recovered from the toxicity and/or complications from the Intervention
Male participants must agree to use approved contraception during the treatment period and for at least 120 days after the last dose of study intervention and refrain from donating sperm during this period
Female participants are not pregnant and not breastfeeding, and are not a woman of childbearing potential (WOCBP) or are a WOCBP who agrees to follow contraceptive guidance during the treatment period and for at least 120 days after the last dose of study intervention
Has adequate organ function

You may not qualify if…

Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days before the first dose of study treatment
Has a known additional malignancy that is progressing or requires active treatment
Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis
Has ocular melanoma
Has known hypersensitivity to active substances or any of their excipients including previous clinically significant hypersensitivity reaction to treatment with another monoclonal antibody
Has an active autoimmune disease that has required systemic treatment in past 2 years (ie, with use of disease modifying agents, corticosteroids or immunosuppressive drugs)
Has an active infection requiring systemic therapy
Has known history of Human Immunodeficiency Virus (HIV) or HIV 1/2 antibodies
Has known history of or is positive for hepatitis B (hepatitis B surface antigen [HBsAg] reactive) or hepatitis C (HCV RNA qualitative] is detected)
Has a history of (non-infectious) pneumonitis/interstitial lung disease that required steroids or current pneumonitis/interstitial lung disease
Has a history of active tuberculosis (Bacillus tuberculosis)
Has presence of a gastrointestinal condition including malabsorption, gastrointestinal anastomosis, or any other condition that might affect the absorption of lenvatinib
Has had major surgery within 4 weeks prior to first dose of study interventions (adequate wound healing after major surgery must be assessed clinically, independent of time elapsed for eligibility)
Has a pre-existing Grade ≥3 gastrointestinal or non-gastrointestinal fistula
Has radiographic evidence of major blood vessel invasion/infiltration
Has clinically significant hemoptysis or tumor bleeding within 2 weeks prior to the first dose of study drug
Has clinically significant cardiovascular disease within 12 months from first dose of study drug, including New York Heart Association Class III or IV congestive heart failure, unstable angina, myocardial infarction, cerebral vascular accident, or cardiac arrhythmia associated with hemodynamic instability
Has received prior radiotherapy within 2 weeks of Cycle 1 Day 1 with the exception of palliative radiotherapy to bone lesions, which is allowed if completed 2 weeks prior to Cycle 1 Day 1
Has received a live vaccine within 30 days before the first dose of study treatment
Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatment
Has a history or has current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the participation for the full duration of the study, or is not in the best interest of the participant to participate, in the opinion of the treating investigator
Has had an allogeneic tissue/solid organ transplant
Has a known psychiatric or substance abuse disorder that would interfere with cooperation with the requirements of the study

Where it is running

Ironwood Cancer & Research Centers ( Site 0312) — Chandler, Arizona, United States
John Wayne Cancer Institute ( Site 0301) — Santa Monica, California, United States
Advocate Medical Group-Park Ridge ( Site 0313) — Park Ridge, Illinois, United States
Southeast Nebraska Cancer Center ( Site 0316) — Lincoln, Nebraska, United States
Texas Oncology-Baylor Charles A. Sammons Cancer Center ( Site 0317) — Dallas, Texas, United States
Inova Schar Cancer Institute ( Site 0314) — Fairfax, Virginia, United States
Melanoma Institute Australia ( Site 0152) — Wollstonecraft, New South Wales, Australia
Princess Alexandra Hospital ( Site 0154) — Woolloongabba, Queensland, Australia
Box Hill Hospital ( Site 0157) — Box Hill, Victoria, Australia
Fiona Stanley Hospital ( Site 0156) — Perth, Western Australia, Australia
Lismore Base Hospital ( Site 0153) — Lismore, Australia
Sunnybrook Research Institute ( Site 0654) — Toronto, Ontario, Canada
Princess Margaret Cancer Centre ( Site 0655) — Toronto, Ontario, Canada
Centre Hospitalier de l Universite de Montreal - CHUM ( Site 0652) — Montreal, Quebec, Canada
McGill University Health Centre ( Site 0651) — Montreal, Quebec, Canada
Hospital Clinic i Provincial Barcelona ( Site 0001) — Barcelona, Spain
Hospital General Universitario Gregorio Maranon ( Site 0003) — Madrid, Spain
Hospital Universitario Virgen de la Macarena ( Site 0004) — Seville, Spain
Hospital General Universitario de Valencia ( Site 0002) — Valencia, Spain
Sahlgrenska Universitetssjukhuset ( Site 0052) — Gothenburg, Sweden
Skanes Universitetssjukhus ( Site 0053) — Lund, Sweden
Karolinska Universitetssjukhuset ( Site 0051) — Solna, Sweden
Norrlands Universitetssjukhus ( Site 0056) — Umeå, Sweden

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.